MME and hydrops fetalis: Recent data demonstrated that sacubitril/valsartan, a combined angiotensin receptor blocker and neprilysin inhibitor, significantly reduced cardiovascular mortality and hospitalization due to worsening HF among HFrEF patients, as compared to an ACEi (160).